Evidence map›Paper›PMID 40879553›Full record

ArticleFuture medicinal chemistry2025

Enhancing oxacillin efficacy against planktonic and biofilms of foodborne Enterobacteriaceae by hylin-a1-derived peptide.

Victor Alves Carneiro, Francisco Figueredo de Lima Filho, Benise Ferreira da Silva, Rafaela Mesquita Bastos Cavalcante, Renata Albuquerque Costa, Esteban Nicolás Lorenzón, Eduardo Maffud Cilli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victor Alves CarneiroCenter for Bioprospecting and Applied Molecular Experimentation (NUBEM), Faculty of Medicine at INTA University Center - UNINTA, Sobral, Brazil.
Francisco Figueredo de Lima FilhoCenter for Bioprospecting and Applied Molecular Experimentation (NUBEM), Faculty of Medicine at INTA University Center - UNINTA, Sobral, Brazil.
Benise Ferreira da SilvaCenter for Bioprospecting and Applied Molecular Experimentation (NUBEM), Faculty of Medicine at INTA University Center - UNINTA, Sobral, Brazil.
Rafaela Mesquita Bastos CavalcanteNortheast Network of Biotechnology Program (RENORBIO), State University of Ceará, Campus Itaperi, Fortaleza, Brazil.
Renata Albuquerque CostaCenter for Bioprospecting and Applied Molecular Experimentation (NUBEM), Faculty of Medicine at INTA University Center - UNINTA, Sobral, Brazil.
Esteban Nicolás LorenzónHealth Science Institute, Federal University of Jataí, Jataí, Brazil.
Eduardo Maffud CilliDepartment of Biochemistry and Organic Chemistry, State University of São Paulo - UNESP, Araraquara, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aims to evaluate the antibacterial and antibiofilm activity of Lys-a1, particularly in combination with oxacillin (OXA), against foodborne MATERIALS AND

methodsThe antibacterial activity was determined by minimum inhibitory/bactericidal concentration (MIC/MBC) and time-kill curves. Additionally, the potential synergistic effects between Lys-a1 and OXA were assessed using a checkerboard assay, and the ability of this combination to disrupt pre-formed biofilms was also investigated.

resultsAll tested strains were sensitive to Lys-a1, exhibiting MIC values ranging from 25 to 100 µg/mL and MBC typically one or twice the MIC values. The time-kill curve indicated the bactericidal effect within 180-240 minutes, achieving a 99.99% reduction in viable cells. Despite the detectable additive action, a notable synergistic effect was observed when Lys-a1 was combined with OXA for most strains (5/8), with an FIC index between 0.31 and 0.50. The Lys-a1/OXA combination significantly reduced biomass by around 50% and 90% of pre-formed biofilms compared with control and OXA-treated and untreated cells, respectively.

conclusionsThe results suggest that Lys-a1/OXA combination could be a promising approach for sensitizing Gram-negative bacteria and expanding treatment options using OXA.

Indexed as

Anti-Bacterial AgentsBiofilmsEnterobacteriaceaeKlebsiellaOxacillinPlanktonDrug SynergismEscherichia coliMicrobial Sensitivity TestsAnti-Bacterial AgentsOxacillinAntimicrobial peptidesEnterobacteriaceaefoodborne illnesseshylin-a1oxacillinsynergism

Identifiers

PMID40879553
PMCPMC12427473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.